The Clinical and Translational Serology Task Force (CTTF) is one of the U.S. National Cancer Institute’s initiatives to respond to the SARS-CoV-2 pandemic.
This is the first installment of its quarterly newsletter. The running publication will include updates about ongoing efforts, information about research, opportunities for communication and collaboration, and notifications about past and upcoming events.
The CTTF was established in January 2021. Its mission is to catalyze translation of research findings into public health changes by bringing together and engaging various government organizations, academic groups, and industry partners to provide relevant tools and information related to serology testing to help decision-makers manage the current and future status of the SARS-CoV-2 pandemic.
Deploying standardized serology testing for the community is among the CTTF’s major aims, as is fully leveraging the power of serology to inform public health changes. The task force strives to facilitate national and international collaborations that use rigor and consistency to meet these goals, expand the community’s understanding of SARS-CoV-2 serology, and illuminate a path forward for the pandemic response.
The CTTF pursues its mission by identifying, coordinating, and uniting. It recognizes existing efforts and gaps in research and communication. It determines appropriate assays for clinical and translational studies and prioritizes unmet needs. Task force members liaise and establish collaborations between clinical and public health groups, including the National Cancer Institute’s Serological Sciences Network and the World Health Organization. They also support public outreach and education about serology.
The approach connects policymakers and stakeholders; clinical, epidemiological, and translational serology teams; and vaccine networks to address SARS-CoV-2 serology. Each group contributes its unique strengths and expertise to a shared vision.
The CTTF is co-chaired by Ligia Pinto, Ph.D., at the Frederick National Laboratory, and Carlos Cordon-Cardo, M.D., Ph.D., at the Icahn School of Medicine at Mount Sinai. Parties with questions about the CTTF can contact Jayne Christen, Ph.D., PMP, at firstname.lastname@example.org.